We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mereo Biopharma Group Plc | LSE:MPH | London | Ordinary Share | GB00BZ4G2K23 | ORD GBP0.003 (REG S) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 26.50 | 26.00 | 27.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMPH
RNS Number : 1267W
Mereo BioPharma Group plc
14 August 2020
Mereo BioPharma Group plc
PDMR Notification
London and Redwood City, Calif ., August 14, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on August 12, 2020 John Richard, Head of Corporate Development of Mereo, purchased 3,500 American Depositary Shares (ADSs) at a price of USD 2.76 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 Details of the person discharging managerial responsibilities a) Name John Richard ------------------------ -------------------------------------------------- 2 Reason for the notification ---------------------------------------------------------------------------- a) Position/status Head of Corporate Development ------------------------ -------------------------------------------------- b) Initial notification/ Initial notification Amendment ------------------------ -------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---------------------------------------------------------------------------- a) Name Mereo BioPharma Group plc ------------------------ -------------------------------------------------- b) LEI 213800U8JQHIJOS5AS09 ------------------------ -------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------------- a) Description of AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES instrument, type OF GBP0.003 EACH of instrument and identification code ------------------------ -------------------------------------------------- b) Nature of the PURCHASE transaction ------------------------ -------------------------------------------------- c) Price(s) and Price(s) Volume(s) volume(s) USD 2.76 3,500 ---------- ------------------------ -------------------------------------------------- d) Aggregated information: volume, Price ------------------------ -------------------------------------------------- e) Date of the transaction 2020-08-12 ------------------------ -------------------------------------------------- f) Place of the XNMS (Nasdaq Global Market) transaction ------------------------ --------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHGGGDIDDBDGGS
(END) Dow Jones Newswires
August 14, 2020 02:00 ET (06:00 GMT)
1 Year Mereo Biopharma Chart |
1 Month Mereo Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions